Diurnal Group plc - DNL

Diurnal Group plc operates as a specialty pharmaceutical company. The company develops hormone therapeutics for the treatment of rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort that is in Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients. The company’s early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; Rheumacor for the treatment of inflammatory diseases; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism; and siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent cushing’s syndrome. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.